Sofwave Medical Q3 revenue climbs 35% on usage fee income
Sofwave Medical's third-quarter revenue rose 35% to $28.5 mln and IFRS net income reached $4.1 mln, according to Reuters.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Reuters, citing the company's report, Sofwave Medical, a maker of devices for regenerative aesthetics, saw third-quarter revenue rise 35% year on year to $28.5 mln. IFRS net income came in at $4.1 mln, up from $1.0 mln a year earlier.
The main driver was recurring fees for using the system, which grew 60% to $13.3 mln as treatment volumes increased across its network of provider clinics. The IFRS gross margin widened to 76.6% from 73.7%.
The company also received NMPA approval to market its system in mainland China and began a staged rollout there late in the quarter. It expects growth opportunities in China and plans to keep investing in clinical development.
why it matters
This is a report from a small company in a niche market, so its reach beyond the sector is limited. Still, the growth in recurring revenue and the China entry suggest the usage-fee model is gaining traction.
tags
instruments
sources
- Sofwave Medical Q3 revenue rises 35% on usage fees — Reuters, 3 November 2026 at 13:44 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗